EMA redistributes UK DCP portfolio

In view of the Brexit, the European Medicine Agency has redistributed the portfolio of the medicinal product for human and veterinary use authorized at central level sharing more than 350 products currently managed by British agencies to rapporteurs and co-rapporteurs of other countries.

At the moment, the staff of the British regulatory Agency (MHRA) and Veterinary Medicines Directorate (VMD) have a leading role in the assessments and processes related to the European Centralized Procedure, however after Brexit it will be no more possible for them to cover such role. The products have been therefore re-assigned to other 27 Member States and to Island and Norway, who took full responsibility of the products starting from last 30 March.

Leave a Reply

Your email address will not be published. Required fields are marked *